INmune Bio, Inc. (NASDAQ:INMB) Receives $8.00 Consensus Target Price from Analysts

Shares of INmune Bio, Inc. (NASDAQ:INMB) have been assigned a consensus recommendation of “Hold” from the six brokerages that are presently covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a sell rating, two have assigned a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $8.00.

Several analysts recently commented on INMB shares. Weiss Ratings restated a “sell (e+)” rating on shares of INmune Bio in a report on Thursday, June 11th. Wall Street Zen cut shares of INmune Bio from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Finally, Lucid Cap Mkts upgraded shares of INmune Bio from a “hold” rating to a “strong-buy” rating in a report on Wednesday, March 11th.

INmune Bio Trading Down 1.4%

INMB stock opened at $1.43 on Tuesday. INmune Bio has a one year low of $1.09 and a one year high of $11.64. The firm has a market capitalization of $38.01 million, a PE ratio of -0.86 and a beta of 1.03. The firm has a 50-day moving average of $1.38 and a two-hundred day moving average of $1.47.

INmune Bio (NASDAQ:INMB) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.20) EPS for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.04.

Hedge Funds Weigh In On INmune Bio

Several institutional investors and hedge funds have recently modified their holdings of the stock. Virtu Financial LLC purchased a new position in shares of INmune Bio during the 4th quarter valued at $32,000. XTX Topco Ltd raised its position in INmune Bio by 41.3% during the fourth quarter. XTX Topco Ltd now owns 68,865 shares of the company’s stock valued at $107,000 after acquiring an additional 20,121 shares in the last quarter. Quadrature Capital Ltd bought a new position in INmune Bio during the fourth quarter valued at approximately $26,000. Jain Global LLC bought a new position in INmune Bio during the fourth quarter valued at approximately $66,000. Finally, Charles Schwab Investment Management Inc. raised its position in INmune Bio by 20.1% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 50,252 shares of the company’s stock valued at $78,000 after acquiring an additional 8,427 shares in the last quarter. 12.72% of the stock is currently owned by hedge funds and other institutional investors.

About INmune Bio

INmune Bio, Inc is a clinical-stage immunology company based in San Diego, California, focused on harnessing the innate immune system to combat a range of serious diseases. The company’s research and development efforts concentrate on modulating cellular pathways to restore and enhance the body’s natural defenses, particularly in oncology and neurodegenerative conditions.

The company’s lead therapeutic candidate, XPro1595 (also referred to as INB03), is a proprietary selective inhibitor of soluble tumor necrosis factor (TNF) designed to reduce chronic inflammation without impairing membrane-bound TNF functions.